Long non-coding RNAs in anti-cancer drug resistance

Oncotarget. 2017 Jan 3;8(1):1925-1936. doi: 10.18632/oncotarget.12461.

Abstract

Chemotherapy is one of the basic treatments for cancers; however, drug resistance is mainly responsible for the failure of clinical treatment. The mechanism of drug resistance is complicated because of interaction among various factors including drug efflux, DNA damage repair, apoptosis and targets mutation. Long non-coding RNAs (lncRNAs) have been a focus of research in the field of bioscience, and the latest studies have revealed that lncRNAs play essential roles in drug resistance in breast cancer, gastric cancer and lung cancer, et al. Dysregulation of multiple targets and pathways by lncRNAs results in the occurrence of chemoresistance. In this review, we will discuss the mechanisms underlying lncRNA-mediated resistance to chemotherapy and the therapeutic potential of lncRNAs in future cancer treatment.

Keywords: cancer; chemotherapy; drug resistance; long non-coding RNAs; targets.

Publication types

  • Review

MeSH terms

  • Apoptosis / genetics
  • Biomarkers, Tumor / genetics
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics*
  • DNA Repair / genetics
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • RNA, Long Noncoding / genetics*
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / genetics*
  • Urinary Bladder Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / genetics*

Substances

  • Biomarkers, Tumor
  • RNA, Long Noncoding